CytRx Corporation is a clinical-stage, biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer. CytRx’s initial focus is on seeking regulatory approval for and commercialization of it’s lead drug candidate, aldoxorubicin, an improved version of the widely used chemotherapeutic agent doxorubicin. Aldoxorubicin is currently in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, and is also being evaluated in several other cancer indications with significant unmet clinical need, including small-cell lung cancer. CytRx plans to expand its pipeline of oncology candidates using its Linker Activated Drug Release, or LADR, technology platform. The company’s LADR…
Author: Alexandra Barnes
The Maryland Technology Development Corporation (TEDCO) announced that two companies received $400,000 in funding through its Life Science Investment Fund (LSIF) – one of TEDCO’s Seed Investment Funds. TEDCO is the go-to source for entrepreneurial support and guidance for start-ups and early-stage companies engaged in bringing innovative ideas to market. For over fifteen years, the organization has provided funding, mentoring and networking opportunities to support Maryland’s innovation ecosystem. It is frequently ranked as one of the most active seed/early-stage investors in the nation. “The Life Science Investment Fund exists to meet the needs of Maryland companies developing products addressing human health that require…
Numerous global public and private initiatives are underway offering exceptional opportunity to revolutionize healthcare delivery. More advanced diagnostic techniques, based on individual patient characteristics including biomarker identification, evidence-based medicine, and a quality over cost time approach are its centerpiece. Personalizing the development of diagnostics and therapeutics, as well as monitoring disease progression and treatment effects, increases the prospect of improved outcomes and population health. BODYQuant’s mission is to provide quantitative measurements of major organs and tissues of the whole body for early disease detection, precision health management, and diagnostic decision support through non-invasive imaging technology. Conceived by a group of accomplished industry…
Guided Therapeutics, the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has reached an agreement with Shandong Yaohua Medical Instrument Corporation in China for exclusive distribution, sales and manufacturing rights of the LuViva® Advanced Cervical Scan for China, Taiwan, Hong Kong and Macau. In addition to a previous payment of $50,000 made by Shandong Yaohua, the terms of the license agreement include a licensing fee by Shandong Yaohua of $1,000,000, the purchase of a minimum of ten LuViva® Advance Cervical Scan devices in 2017 and royalties for disposables based on…
CivaTech Oncology, Inc., Corporation, a North Carolina-based company focused on localized radiation therapy, submitted a Form D for a $2.72M debt financing. The date of first sale was December 9, 2015, where the company was able to fundraise $2.71 million, or 99.64% of the offering. On average, companies in similar fields sell 68.60% of the total offering amount. The total private offering amount was $2.72 million. The fundraising form was filed on December 16. 2016. CivaTech cited that the reason for the financing was to exclude salaries paid in the ordinary course of business.. The fundraising still has $9,780 remaining and is…
Creatv MicroTech is a company that understands that cancer will, at some point, likely touch us, our families and friends. In the U.S. alone, 43% of men and 38% of women will develop cancer in their lifetimes. Cancer detected early at curable stage can result in high probability of long term survival. For example, early detection has greatly improved treatment outcomes for breast and colorectal cancers, but screening methods are limited or non-existent for most other cancers. There is pressing need for a low cost, non-invasive method for early detection of cancer, to monitor for recurrence, and to determine residual…
CivaTech Oncology, Inc. (“CivaTech” or the “Company”) has developed a major technological advance in the radiation treatment of cancerous tumors. CivaTech products significantly reduce the side effects experienced from traditional implantable radiation sources or external beam methods while providing meaningfully higher doses of radiation not previously possible without irreversible damage to surrounding healthy tissue. The ability to protect healthy tissue is a disruptive technology and for many indications, will become the standard of care. Both products are the first polymer encapsulation of radiation without the use of stainless steel or other metals. The company has four patents issued with two FDA 510K…
Valisure is a start-up company founded in 2015 in New Haven, CT by a group of Yale and Harvard alumni with proven biotech industry success (recent exit: Ion Torrent $725M). Valisure’s disruptive technology in the pharmaceutical analysis space has broad application but the team has focused on the rapidly growing direct-to-consumer lab testing market which has seen a dramatic inflection point in the last few years ($17M market in 2011, $131M in 2015) and has been bolstered by the recent entry of major companies like LabCorp and Quest Diagnostics. Unlike the other 20+ companies that have quickly populated the direct-to-consumer…